M.L. Nava

742 total citations
11 papers, 640 citations indexed

About

M.L. Nava is a scholar working on Surgery, Molecular Biology and Pharmacology. According to data from OpenAlex, M.L. Nava has authored 11 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 3 papers in Molecular Biology and 3 papers in Pharmacology. Recurrent topics in M.L. Nava's work include Lipoproteins and Cardiovascular Health (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers) and Respiratory and Cough-Related Research (2 papers). M.L. Nava is often cited by papers focused on Lipoproteins and Cardiovascular Health (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers) and Respiratory and Cough-Related Research (2 papers). M.L. Nava collaborates with scholars based in United States and Italy. M.L. Nava's co-authors include John W. Gaubatz, John R. Guyton, Wolfgang Patsch, Juan Guevara, Mohan V. Chari, J D Morrisett, Donald Weilbaecher, Thomas Bocan, Michael E. DeBakey and Joel D. Morrisett and has published in prestigious journals such as Journal of Lipid Research, Drugs and European Journal of Clinical Investigation.

In The Last Decade

M.L. Nava

11 papers receiving 606 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.L. Nava United States 7 452 218 170 121 99 11 640
Carol L. Heideman United States 10 520 1.2× 249 1.1× 193 1.1× 123 1.0× 132 1.3× 12 766
B Kishino Japan 12 412 0.9× 79 0.4× 243 1.4× 126 1.0× 154 1.6× 28 753
Patti Polinsky United States 7 197 0.4× 92 0.4× 129 0.8× 130 1.1× 140 1.4× 8 697
J L Adolphson United States 13 584 1.3× 244 1.1× 369 2.2× 107 0.9× 262 2.6× 19 890
Adam W. Grasso United States 5 411 0.9× 138 0.6× 249 1.5× 148 1.2× 261 2.6× 6 883
G. Luc France 10 301 0.7× 148 0.7× 394 2.3× 356 2.9× 123 1.2× 15 803
E. de Wit Netherlands 16 297 0.7× 164 0.8× 240 1.4× 146 1.2× 347 3.5× 26 771
Harald Torsvik Norway 15 330 0.7× 153 0.7× 170 1.0× 68 0.6× 141 1.4× 29 604
Junichiro Tohyama United States 14 381 0.8× 166 0.8× 245 1.4× 118 1.0× 240 2.4× 17 790
Tiziana Sampietro Italy 18 594 1.3× 156 0.7× 356 2.1× 299 2.5× 195 2.0× 75 1.1k

Countries citing papers authored by M.L. Nava

Since Specialization
Citations

This map shows the geographic impact of M.L. Nava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.L. Nava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.L. Nava more than expected).

Fields of papers citing papers by M.L. Nava

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.L. Nava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.L. Nava. The network helps show where M.L. Nava may publish in the future.

Co-authorship network of co-authors of M.L. Nava

This figure shows the co-authorship network connecting the top 25 collaborators of M.L. Nava. A scholar is included among the top collaborators of M.L. Nava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.L. Nava. M.L. Nava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Zuckermann, Michele, Rebecca Panconesi, I. Scaricabarozzi, M.L. Nava, & Paolo Bechi. (1993). Clinical Efficacy and Tolerability of Nimesulide Compared with Naproxen in the Treatment of Posthaemorrhoidectomy Pain and Inflammation. Drugs. 46(Supplement 1). 177–179. 11 indexed citations
3.
Barberi, Ignazio, et al.. (1993). Double-Blind Evaluation of Nimesulide vs Lysine-Aspirin in the Treatment of Paediatric Acute Respiratory Tract Infections. Drugs. 46(Supplement 1). 219–221. 7 indexed citations
5.
Castoldi, D, et al.. (1991). First dose and steady state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers.. PubMed. 46(9). 1071–9. 23 indexed citations
6.
Guevara, Juan, et al.. (1990). Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a].. Journal of Lipid Research. 31(4). 603–613. 225 indexed citations
7.
Gaubatz, John W., M.L. Nava, Thomas Bocan, et al.. (1989). Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.. Arteriosclerosis An Official Journal of the American Heart Association Inc. 9(5). 593–603. 220 indexed citations
8.
Castoldi, D, et al.. (1988). Pharmacokinetics of nimesulide and hydroxynimesulide in healthy subjects. Pharmacological Research Communications. 20. 193–193. 2 indexed citations
9.
Gaubatz, John W., Mohan V. Chari, M.L. Nava, John R. Guyton, & J D Morrisett. (1986). Isolation and characterization of the two major apoproteins in human lipoprotein [a].. Journal of Lipid Research. 28(1). 69–79. 109 indexed citations
10.
Facino, Roberto Maffei, M. Carini, M.L. Nava, & O. Tofanetti. (1983). Effects of chronic tiadenol administration on liver microsomal cytochrome P-450 and associated monooxygenases in the rat.. PubMed. 38(12). 429–38. 1 indexed citations
11.
Thompson, Gilbert R., A Jadhav, M.L. Nava, & Antonio M. Gotto. (1976). Effects of Intravenous Phospholipid on Low Density Lipoprotein Turnover in Man*. European Journal of Clinical Investigation. 6(1). 241–248. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026